Rekombinanter PCSK9 (Bococizumab Biosimilar) Antikörper
Reaktivität: Human
ELISA, FACS, SPR, Func, BLI
Wirt: Human
Monoclonal
unconjugated
Recombinant Antibody
-
- Target Alle PCSK9 (Bococizumab Biosimilar) Produkte
- PCSK9 (Bococizumab Biosimilar)
- Antikörpertyp
- Recombinant Antibody
- Reaktivität
- Human
-
Wirt
-
Human
- Expressionssystem
- CHO Cells
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser PCSK9 (Bococizumab Biosimilar) Antikörper ist unkonjugiert
- Applikation
- ELISA, Flow Cytometry (FACS), Surface Plasmon Resonance (SPR), Functional Studies (Func), Bio-Layer Interferometry (BLI)
- Verwendungszweck
- Anti-PCSK9 Reference Antibody (bococizumab)
- Sequenz
- QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYYMHWVRQA PGQGLEWMGE ISPFGGRTNY NEKFKSRVTM TRDTSTSTVY MELSSLRSED TAVYYCARER PLYASDLWGQ GTTVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT CNVDHKPSNT KVDKTVERKC CVECPPCPAP PVAGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTFRVV SVLTVVHQDW LNGKEYKCKV SNKGLPSSIE KTISKTKGQP REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPMLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK,DIQMTQSPSS LSASVGDRVT ITCRASQGIS SALAWYQQKP GKAPKLLIYS ASYRYTGVPS RFSGSGSGTD FTFTISSLQP EDIATYYCQQ RYSLWRTFGQ GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
- Produktmerkmale
- Anti-PCSK9 Reference Antibody (bococizumab) is expressed from CHO. The heavy chain type is huIgG2, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
- Reinheit
- >95 %
- Isotyp
- IgG2SA
-
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Kommentare
-
Therapeutic Agents by Target and Mechanism: PCSK9 inhibitors
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Konzentration
- 1 mg/mL
- Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
- Lagerung
- 4 °C,-80 °C
- Informationen zur Lagerung
- +4°C,-80°C
-
- Target
- PCSK9 (Bococizumab Biosimilar)
- Abstract
- PCSK9 (Bococizumab Biosimilar) Produkte
- Substanzklasse
- Biosimilar
- Molekulargewicht
- 145.5 kDa
- UniProt
- Q8NBP7
-
Sie sind hier:
